Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples

Despite the promising impact of cancer immunotherapy targeting CTLA4 and PD1/PDL1, numerous cancer patients fail to respond. LAG3 (Lymphocyte Activating 3), also named CD233, serves as an alternative inhibitory receptor to be targeted in the clinic. The impacts of LAG3 on immune cell populations and...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qiang, Qi, Yihang, Zhai, Jie, Kong, Xiangyi, Wang, Xiangyu, Wang, Zhongzhao, Fang, Yi, Wang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276078/
https://www.ncbi.nlm.nih.gov/pubmed/34267742
http://dx.doi.org/10.3389/fimmu.2021.599207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276078/
https://www.ncbi.nlm.nih.gov/pubmed/34267742
http://dx.doi.org/10.3389/fimmu.2021.599207

Ejemplares similares